Copyright
©The Author(s) 2019.
World J Clin Cases. Apr 26, 2019; 7(8): 972-983
Published online Apr 26, 2019. doi: 10.12998/wjcc.v7.i8.972
Published online Apr 26, 2019. doi: 10.12998/wjcc.v7.i8.972
Table 5 Immunohistochemistry markers of hepatic epithelioid angiomyolipoma
Markers | Positive/weakly positive/negative (+/±/-) | Positive rate |
HMB45 | 219/2/5 | 97.35% |
S-100 | 19/5/63 | 24.71% |
SMA | 128/15/32 | 77.43% |
MSA | 4/10/1 | 60% |
Actin | 32/1/5 | 85.53% |
Melan-A | 91/1/22 | 80.70% |
CD31 | 2/0/2 | 50% |
CD34 | 38/0/34 | 52.78% |
CD68 | 2/6/5 | 33.33% |
CD117 | 0/0/13 | 0% |
Vimentin | 23/11/17 | 55.88% |
Kpan | 0/0/101 | 0% |
HepPar-1 | 0/0/52 | 0% |
MAC387 | 6/0/0 | 100% |
EMA | 0/0/30 | 0% |
Desmin | 0/20/30 | 20% |
MART-1 | 24/0/1 | 96% |
CEA | 1/0/9 | 10% |
AFP | 0/1/66 | 0.75% |
MPO | 0/1/1 | 25% |
p53 | 0/0/9 | 0% |
E-cadherin, b-cadherin | 0/1/4 | 10% |
pp70S6K | 1/2/1 | 50% |
MyoD1 | 2/2/1 | 60% |
- Citation: Mao JX, Teng F, Liu C, Yuan H, Sun KY, Zou Y, Dong JY, Ji JS, Dong JF, Fu H, Ding GS, Guo WY. Two case reports and literature review for hepatic epithelioid angiomyolipoma: Pitfall of misdiagnosis. World J Clin Cases 2019; 7(8): 972-983
- URL: https://www.wjgnet.com/2307-8960/full/v7/i8/972.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i8.972